

Jerome Galon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2219760/publications.pdf>

Version: 2024-02-01

216
papers

51,148
citations

5126

86
h-index

2402

204
g-index

231
all docs

231
docs citations

231
times ranked

57212
citing authors

#	ARTICLE	IF	CITATIONS
1	The "Immunescore" in rectal cancer: could we search quality beyond quantity of life?. <i>Oncotarget</i> , 2022, 13, 18-31.	0.8	3
2	Immune sunrise: from the immunome to the cancer immune landscape. <i>Oncolimmunology</i> , 2022, 11, 2019896.	2.1	5
3	Comparison of Immune Response Assessment in Colon Cancer by Immunescore (Automated Digital) Tj ETQq1 1 0.784314 rgBT /Over	1.7	6
4	Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. <i>Cell</i> , 2022, 185, 1189-1207.e25.	13.5	166
5	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3053-3065.	3.2	26
6	Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunescore Are Associated with a Pathological Complete Response. <i>Cancers</i> , 2022, 14, 2525.	1.7	12
7	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
8	Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7565-7565.	0.8	4
9	Prognostic assessment of resected colorectal liver metastases integrating pathological features, <sc>RAS</sc> mutation and Immunescore. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 27-41.	1.3	24
10	Evasion before invasion: Pre-cancer immunosurveillance. <i>Oncolimmunology</i> , 2021, 10, 1912250.	2.1	9
11	Tumor spread or siege immunity: dissemination to distant metastasis or not. <i>Oncolimmunology</i> , 2021, 10, 1919377.	2.1	7
12	Expand to shield: IL-15 and <i>in situ</i> lymphocytic proliferation. <i>Oncolimmunology</i> , 2021, 10, 1886726.	2.1	6
13	Precision immunity: Immunescore and neoadjuvant treatment in bladder cancer. <i>Oncolimmunology</i> , 2021, 10, 1888488.	2.1	9
14	Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2755-2763.	3.2	29
15	Germline genetic contribution to the immune landscape of cancer. <i>Immunity</i> , 2021, 54, 367-386.e8.	6.6	95
16	Therapeutic Implications of the Immunescore in Patients with Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1281.	1.7	14
17	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd,) Tj ETQq1 1 0.784314 rgBT /Ov	1.8	1
18	Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion. <i>Cell</i> , 2021, 184, 5230-5246.e22.	13.5	109

#	ARTICLE	IF	CITATIONS
19	The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival. <i>Cancers</i> , 2021, 13, 494.	1.7	10
20	Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. <i>Journal of Immunotherapy</i> , 2021, 44, 49-62.	1.2	7
21	License to kill: microsatellite instability and immune contexture. <i>Oncolmunology</i> , 2021, 10, 1905935.	2.1	10
22	Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)â€”A proof of concept, open-label, nonrandomized phase IIa study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 80-80.	0.8	18
23	The Immunoscore: Colon Cancer and Beyond. <i>Clinical Cancer Research</i> , 2020, 26, 332-339.	3.2	255
24	A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 5198-5207.	3.2	66
25	The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. <i>Nature Reviews Cancer</i> , 2020, 20, 662-680.	12.8	860
26	Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3073.	1.7	28
27	Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patients. <i>Oncolmunology</i> , 2020, 9, 1826133.	2.1	4
28	Usefulness and robustness of Immunoscore for personalized management of cancer patients. <i>Oncolmunology</i> , 2020, 9, 1832324.	2.1	11
29	Multiverse of immune microenvironment in metastatic colorectal cancer. <i>Oncolmunology</i> , 2020, 9, 1824316.	2.1	9
30	No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study. <i>Oncolmunology</i> , 2020, 9, 1826132.	2.1	10
31	Metastasis immune-based scores predict patient survival. <i>Oncolmunology</i> , 2020, 9, 1806000.	2.1	4
32	The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions. <i>Oncolmunology</i> , 2020, 9, 1812221.	2.1	15
33	The consensus immunoscore: toward a new classification of colorectal cancer. <i>Oncolmunology</i> , 2020, 9, 1789032.	2.1	25
34	The Great Debate at â€”Immunotherapy Bridgeâ€™, Naples, December 5, 2019. , 2020, 8, e000921.		3
35	The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions. <i>Oncolmunology</i> , 2020, 9, 1796003.	2.1	3
36	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3638-3651.	0.8	130

#	ARTICLE	IF	CITATIONS
37	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57
38	Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI Cancer Spectrum, 2020, 4, pkaa023.	1.4	36
39	Immunoscore assay for the immune classification of solid tumors: Technical aspects, improvements and clinical perspectives. Methods in Enzymology, 2020, 636, 109-128.	0.4	13
40	Multiplexed immunohistochemistry for immune cell phenotyping, quantification and spatial distribution in situ. Methods in Enzymology, 2020, 635, 51-66.	0.4	14
41	Tumor Immunology and Tumor Evolution: Intertwined Histories. Immunity, 2020, 52, 55-81.	6.6	357
42	Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer. Cell Death and Disease, 2020, 11, 275.	2.7	21
43	The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications. Cancer Treatment and Research, 2020, 180, 197-211.	0.2	4
44	Phenotyping of tumor infiltrating immune cells using mass-cytometry (CyTOF). Methods in Enzymology, 2020, 632, 339-368.	0.4	17
45	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nature Medicine, 2020, 26, 919-931.	15.2	118
46	Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. , 2020, 8, e000272.		43
47	Immunoscore and its introduction in clinical practice. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 152-161.	0.4	48
48	Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).. Journal of Clinical Oncology, 2020, 38, 10-10.	0.8	1
49	Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature, 2019, 571, 570-575.	13.7	227
50	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
51	Automated exploration of gene ontology term and pathway networks with ClueGO-REST. Bioinformatics, 2019, 35, 3864-3866.	1.8	48
52	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature Reviews Drug Discovery, 2019, 18, 197-218.	21.5	2,005
53	Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).. Journal of Clinical Oncology, 2019, 37, 3513-3513.	0.8	8
54	Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.. Journal of Clinical Oncology, 2019, 37, 487-487.	0.8	15

#	ARTICLE	IF	CITATIONS
55	Comprehensive functional analysis of large lists of genes and proteins. <i>Journal of Proteomics</i> , 2018, 171, 2-10.	1.2	80
56	Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival. <i>Journal of the National Cancer Institute</i> , 2018, 110, 97-108.	3.0	199
57	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278
58	The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. <i>Cancer Cell</i> , 2018, 34, 1012-1026.e3.	7.7	209
59	Quantifying Immunoscore performance – Authors' reply. <i>Lancet, The</i> , 2018, 392, 1624-1625.	6.3	3
60	Clinical Response in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma, May Be Influenced by Characteristics of the Pretreatment Tumor Microenvironment (TME). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S281.	0.2	1
61	Evolution of Metastases in Space and Time under Immune Selection. <i>Cell</i> , 2018, 175, 751-765.e16.	13.5	322
62	Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2018, 9, 1044.	2.2	107
63	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) <i>Tj ETQq1 1 0.784314 rgBT</i>		12
64	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018, 391, 2128-2139.	6.3	1,487
65	Hafnium oxide nanoparticle activated by radiotherapy to generate an anti-tumor immune response.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15149-e15149.	0.8	2
66	Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147;) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>		10
67	Abstract IA12: Integrative genomics and immune contexture approach to immuno-oncology. , 2018, ,		0
68	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
69	Regulation of CTL Infiltration Within the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 33-49.	0.8	25
70	Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). <i>Annals of Oncology</i> , 2017, 28, iii153.	0.6	1
71	Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3025-3025.	0.8	42
72	Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3579-3579.	0.8	9

#	ARTICLE	IF	CITATIONS
73	Specific adaptive immune pattern induced by NBTXR3 exposed to radiation therapy in soft tissue sarcoma (STS) patients.. Journal of Clinical Oncology, 2017, 35, e14615-e14615.	0.8	3
74	Abstract 590: A new standardized CD8 and PD-L1 dual assay. , 2017, , .		0
75	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. International Immunology, 2016, 28, 373-382.	1.8	143
76	Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification. Journal of the National Cancer Institute, 2016, 108, djw033.	3.0	19
77	T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell, 2016, 30, 377-390.	7.7	141
78	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology, 2016, 5, e1214790.	2.1	64
79	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. , 2016, 4, 37.		1
80	31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. , 2016, 4, .		11
81	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67
82	Trial Watch“Immunostimulation with cytokines in cancer therapy. Oncoimmunology, 2016, 5, e1115942.	2.1	52
83	Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity, 2016, 44, 698-711.	6.6	814
84	Frameshift mutations, neoantigens and tumor-specific CD8 ⁺ T cells in microsatellite unstable colorectal cancers. Oncoimmunology, 2016, 5, e1115943.	2.1	45
85	The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Science Translational Medicine, 2016, 8, 327ra26.	5.8	360
86	Trial Watch“Oncolytic viruses and cancer therapy. Oncoimmunology, 2016, 5, e1117740.	2.1	88
87	Trial Watch“Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology, 2016, 5, e1149674.	2.1	46
88	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology, 2016, 5, e1057388.	2.1	239
89	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology, 2016, 5, e1088631.	2.1	104
90	Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.. Journal of Clinical Oncology, 2016, 34, 3500-3500.	0.8	57

#	ARTICLE	IF	CITATIONS
91	Abstract A114: Towards personalized cellular adoptive immunotherapy targeting tumor specific neo-antigens in microsatellite unstable colorectal cancers. , 2016, , .		0
92	Abstract 1419: Characterization of the evolution of immune response in lung squamous carcinogenesis. , 2016, , .		1
93	From mice to humans: developments in cancer immunoediting. <i>Journal of Clinical Investigation</i> , 2015, 125, 3338-3346.	3.9	271
94	Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. <i>Cancer Research</i> , 2015, 75, 3446-3455.	0.4	210
95	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e985940.	2.1	47
96	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e974411.	2.1	97
97	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1008814.	2.1	102
98	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008866.	2.1	237
99	Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. <i>Genome Biology</i> , 2015, 16, 64.	3.8	433
100	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
101	Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse. <i>Immunity</i> , 2015, 43, 631-633.	6.6	50
102	Trial Watch: Adoptive cell transfer for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1046673.	2.1	29
103	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e1026531.	2.1	26
104	Characterization of the immune microenvironment of synchronous primary tumor and liver colorectal metastases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3610-3610.	0.8	1
105	Preoperative treatment to modify the immune microenvironment of liver colorectal metastases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 602-602.	0.8	12
106	Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. <i>Oncotarget</i> , 2015, 6, 11894-11909.	0.8	39
107	Prognostic association of FoxP3 regulatory T cells with tumor infiltrating CD8 cytotoxic T cells quantified on resected liver colorectal metastases (LCM).. <i>Journal of Clinical Oncology</i> , 2015, 33, e14643-e14643.	0.8	0
108	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395

#	ARTICLE	IF	CITATIONS
109	Trial watch. <i>Oncolimmunology</i> , 2014, 3, e29030.	2.1	51
110	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolimmunology</i> , 2014, 3, e955691.	2.1	686
111	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e29179.	2.1	76
112	Trial Watch: Radioimmunotherapy for oncological indications. <i>Oncolimmunology</i> , 2014, 3, e954929.	2.1	40
113	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e27048.	2.1	69
114	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e28185.	2.1	36
115	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e27297.	2.1	99
116	The immune landscape of human tumors. <i>Oncolimmunology</i> , 2014, 3, e27456.	2.1	97
117	Trial Watch:. <i>Oncolimmunology</i> , 2014, 3, e28694.	2.1	95
118	Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. <i>Oncolimmunology</i> , 2014, 3, e27884.	2.1	74
119	Trial watch: Dendritic cell-based anticancer therapy. <i>Oncolimmunology</i> , 2014, 3, e963424.	2.1	62
120	Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients. <i>Science Translational Medicine</i> , 2014, 6, 228ra37.	5.8	181
121	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. , 2014, , 37-51.		0
122	779 CXCL13-CXCR5 Signaling Is Required for the Anti-Tumor Immune Response in Colorectal Cancer. <i>Gastroenterology</i> , 2014, 146, S-131.	0.6	1
123	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e27878.	2.1	134
124	Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1891-1899.	3.2	298
125	30: From the immune contexture to the Immunoscore in cancer. <i>European Journal of Cancer</i> , 2014, 50, S8.	1.3	1
126	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e28344.	2.1	31

#	ARTICLE	IF	CITATIONS
127	Towards the introduction of the "Immunoscore"™ in the classification of malignant tumours. Journal of Pathology, 2014, 232, 199-209.	2.1	1,151
128	The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. Journal of Translational Medicine, 2013, 11, 54.	1.8	104
129	The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact. Cancer Microenvironment, 2013, 6, 117-122.	3.1	119
130	Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012. , 2013, 1, 9.		3
131	Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer. Immunity, 2013, 39, 782-795.	6.6	2,983
132	From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Current Opinion in Immunology, 2013, 25, 261-267.	2.4	444
133	The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. Immunity, 2013, 39, 11-26.	6.6	700
134	Trial watch. OncoImmunology, 2013, 2, e23803.	2.1	92
135	Trial watch. OncoImmunology, 2013, 2, e25771.	2.1	150
136	Trial Watch: Lenalidomide-based immunochemotherapy. OncoImmunology, 2013, 2, e26494.	2.1	50
137	Trial watch. OncoImmunology, 2013, 2, e22789.	2.1	92
138	Trial watch. OncoImmunology, 2013, 2, e23510.	2.1	153
139	Trial Watch. OncoImmunology, 2013, 2, e26621.	2.1	101
140	Trial Watch. OncoImmunology, 2013, 2, e24238.	2.1	58
141	Trial Watch. OncoImmunology, 2013, 2, e24850.	2.1	49
142	Trial Watch. OncoImmunology, 2013, 2, e25595.	2.1	83
143	Trial Watch. OncoImmunology, 2013, 2, e25238.	2.1	132
144	CluePedia Cytoscape plugin: pathway insights using integrated experimental and <i>in silico</i> data. Bioinformatics, 2013, 29, 661-663.	1.8	958

#	ARTICLE	IF	CITATIONS
145	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e24612.	2.1	175
146	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. <i>Oncolimmunology</i> , 2012, 1, 894-907.	2.1	194
147	Trial watch. <i>Oncolimmunology</i> , 2012, 1, 179-188.	2.1	104
148	Trial watch. <i>Oncolimmunology</i> , 2012, 1, 1557-1576.	2.1	110
149	Trial Watch. <i>Oncolimmunology</i> , 2012, 1, 699-739.	2.1	184
150	Trial Watch. <i>Oncolimmunology</i> , 2012, 1, 306-315.	2.1	70
151	Trial Watch. <i>Oncolimmunology</i> , 2012, 1, 493-506.	2.1	86
152	Integrating Biomolecular and Clinical Data for Cancer Research: Concepts and Challenges. , 2012, , 159-172.		0
153	Bioinformatics for cancer immunology and immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1885-1903.	2.0	40
154	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012, 10, 205.	1.8	676
155	Toward integrative cancer immunotherapy: targeting the tumor microenvironment. <i>Journal of Translational Medicine</i> , 2012, 10, 70.	1.8	53
156	Trial watch. <i>Oncolimmunology</i> , 2012, 1, 1111-1134.	2.1	152
157	Trial Watch: Monoclonal antibodies in cancer therapy. <i>Oncolimmunology</i> , 2012, 1, 28-37.	2.1	103
158	Trial watch. <i>Oncolimmunology</i> , 2012, 1, 1323-1343.	2.1	203
159	The immune contexture in human tumours: impact on clinical outcome. <i>Nature Reviews Cancer</i> , 2012, 12, 298-306.	12.8	3,873
160	The immune score as a new possible approach for the classification of cancer. <i>Journal of Translational Medicine</i> , 2012, 10, 1.	1.8	656
161	Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction. <i>Journal of Clinical Oncology</i> , 2011, 29, 610-618.	0.8	864
162	Defining the critical hurdles in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 214.	1.8	139

#	ARTICLE	IF	CITATIONS
163	Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates. <i>Cancer Research</i> , 2011, 71, 5601-5605.	0.4	341
164	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. <i>Frontiers in Immunology</i> , 2011, 2, 66.	2.2	9
165	Cancer immunology's analysis of host and tumor factors for personalized medicine. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 711-719.	12.5	251
166	Tumor immunosurveillance in human cancers. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 5-12.	2.7	170
167	hSMG-1 is a granzyme B-associated stress-responsive protein kinase. <i>Journal of Molecular Medicine</i> , 2011, 89, 411-421.	1.7	9
168	The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. <i>Seminars in Immunopathology</i> , 2011, 33, 335-340.	2.8	97
169	Immunosurveillance in human non-viral cancers. <i>Current Opinion in Immunology</i> , 2011, 23, 272-278.	2.4	46
170	Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer. <i>Cancer Research</i> , 2011, 71, 1263-1271.	0.4	986
171	Information technology solutions for integration of biomolecular and clinical data in the identification of new cancer biomarkers and targets for therapy. , 2010, 128, 488-498.		13
172	Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction. <i>BMC Genomics</i> , 2010, 11, S7.	1.2	16
173	Natural immunity to cancer in humans. <i>Current Opinion in Immunology</i> , 2010, 22, 215-222.	2.4	153
174	Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer. <i>Gastroenterology</i> , 2010, 138, 1429-1440.	0.6	280
175	Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 1-24.	0.7	193
176	Memory T-Cell Responses and Survival in Human Cancer: Remember to Stay Alive. <i>Advances in Experimental Medicine and Biology</i> , 2010, 684, 166-177.	0.8	9
177	ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. <i>Bioinformatics</i> , 2009, 25, 1091-1093.	1.8	5,348
178	In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5944-5951.	0.8	822
179	Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence. <i>Cancer Research</i> , 2009, 69, 2685-2693.	0.4	262
180	The essential role of the in situ immune reaction in human colorectal cancer. <i>Journal of Leukocyte Biology</i> , 2008, 84, 981-987.	1.5	106

#	ARTICLE	IF	CITATIONS
181	The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective: Figure 1.. Cancer Research, 2007, 67, 1883-1886.	0.4	386
182	Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science, 2006, 313, 1960-1964.	6.0	5,356
183	Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1428-1433.	3.3	51
184	Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood, 2005, 105, 1632-1639.	0.6	26
185	Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer. New England Journal of Medicine, 2005, 353, 2654-2666.	13.9	1,860
186	Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB Journal, 2002, 16, 61-71.	0.2	510
187	Cybr, a cytokine-inducible protein that binds cytohesin-1 and regulates its activity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 2625-2629.	3.3	39
188	Positive Effects of Glucocorticoids on T Cell Function by Up-Regulation of IL-7 Receptor $\hat{\pm}$. Journal of Immunology, 2002, 168, 2212-2218.	0.4	142
189	Glucocorticoids and Inflammation Revisited: The State of the Art. NeuroImmunoModulation, 2002, 10, 247-260.	0.9	107
190	Modulation of tumor growth by inhibitory Fc $\hat{\gamma}$ 3 receptor expressed by human melanoma cells. Journal of Clinical Investigation, 2002, 110, 1549-1557.	3.9	29
191	Modulation of tumor growth by inhibitory Fc $\hat{\gamma}$ 3 receptor expressed by human melanoma cells. Journal of Clinical Investigation, 2002, 110, 1549-1557.	3.9	12
192	The Tumor-Necrosis-Factor Receptor-associated Periodic Syndrome: New Mutations in TNFRSF1A, Ancestral Origins, Genotype-Phenotype Studies, and Evidence for Further Genetic Heterogeneity of Periodic Fevers. American Journal of Human Genetics, 2001, 69, 301-314.	2.6	328
193	Positive effects of glucocorticoids on T cell function and development by upregulation of interleukin-7 receptor $\hat{\pm}$. Gastroenterology, 2001, 120, A314-A315.	0.6	0
194	Soluble CD16 Inhibits CR3 (CD11b/CD18)-Mediated Infection of Monocytes/Macrophages by Opsonized Primary R5 HIV-1. Journal of Immunology, 2001, 166, 3377-3383.	0.4	32
195	TNFRSF1A mutations and autoinflammatory syndromes. Current Opinion in Immunology, 2000, 12, 479-486.	2.4	224
196	Do glucocorticoids participate in thymocyte development?. Trends in Immunology, 2000, 21, 644-645.	7.5	37
197	The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood, 2000, 95, 3223-3231.	0.6	356
198	Stat4 Is Expressed in Activated Peripheral Blood Monocytes, Dendritic Cells, and Macrophages at Sites of Th1-Mediated Inflammation. Journal of Immunology, 2000, 164, 4659-4664.	0.4	168

#	ARTICLE	IF	CITATIONS
199	Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes. <i>Journal of Immunology</i> , 2000, 164, 1768-1774.	0.4	228
200	Hierarchy of Protein Tyrosine Kinases in Interleukin-2 (IL-2) Signaling: Activation of Syk Depends on Jak3; However, Neither Syk nor Lck Is Required for IL-2-Mediated STAT Activation. <i>Molecular and Cellular Biology</i> , 2000, 20, 4371-4380.	1.1	35
201	Inhibition of TH1 immune response by glucocorticoids: Dexamethasone inhibits IL-12-induced stat4 phosphorylation in T lymphocytes. <i>Gastroenterology</i> , 2000, 118, A790-A791.	0.6	1
202	Functional and morphological adrenal changes in TNBS-induced colitis. <i>Gastroenterology</i> , 2000, 118, A343.	0.6	0
203	Adrenal cortical activation in murine colitis. <i>Gastroenterology</i> , 2000, 119, 1560-1568.	0.6	46
204	The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. <i>Blood</i> , 2000, 95, 3223-3231.	0.6	13
205	Presentation of Antigen in Immune Complexes Is Boosted by Soluble Bacterial Immunoglobulin Binding Proteins. <i>Journal of Experimental Medicine</i> , 1999, 189, 1217-1228.	4.2	11
206	Regulation of production of soluble Fc γ 3 receptors type III in normal and pathological conditions. <i>Immunology Letters</i> , 1999, 68, 125-134.	1.1	41
207	Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes. <i>Cell</i> , 1999, 97, 133-144.	13.5	1,271
208	Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). <i>European Journal of Immunology</i> , 1998, 28, 2101-2107.	1.6	40
209	Cytokines et cellules dendritiques.. <i>Medecine/Sciences</i> , 1998, 14, 429.	0.0	1
210	Soluble Fc γ 3 Receptors: Interaction with Ligands and Biological Consequences. <i>International Reviews of Immunology</i> , 1997, 16, 87-111.	1.5	19
211	A New Set of Monoclonal Antibodies Against Human Fc γ 3RII (CD32) and Fc γ 3RIII (CD16): Characterization and Use in Various Assays. <i>Hybridoma</i> , 1997, 16, 519-528.	0.9	35
212	Affinity of the interaction between Fc gamma receptor type III (Fc γ 3RIII) and monomeric human IgG subclasses. Role of Fc γ 3RIII glycosylation. <i>European Journal of Immunology</i> , 1997, 27, 1928-1932.	1.6	49
213	Regulation of CD44 Isoform Expression and CD44-Mediated Signaling in Human Dendritic Cells. <i>Advances in Experimental Medicine and Biology</i> , 1997, 417, 83-90.	0.8	8
214	Ligands and biological activities of soluble Fc γ 3 receptors. <i>Immunology Letters</i> , 1995, 44, 175-181.	1.1	26
215	Soluble Fc γ 3 receptors. <i>Journal of Leukocyte Biology</i> , 1993, 54, 504-512.	1.5	59
216	Janus Kinases and STAT Family Transcription Factors: Their Role in the Function and Development of Lymphoid Cells. , 0, , 229-254.		0